RT Journal Article
SR Electronic
T1 Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Deep Learning Enabled Clinical Decision Support System for Personalized Depression Treatment Selection and Management
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.13.24308884
DO 10.1101/2024.06.13.24308884
A1 Benrimoh, David
A1 Whitmore, Kate
A1 Richard, Maud
A1 Golden, Grace
A1 Perlman, Kelly
A1 Jalali, Sara
A1 Friesen, Timothy
A1 Barkat, Youcef
A1 Mehltretter, Joseph
A1 Fratila, Robert
A1 Armstrong, Caitrin
A1 Israel, Sonia
A1 Popescu, Christina
A1 Karp, Jordan F.
A1 Parikh, Sagar V.
A1 Golchi, Shirin
A1 Moodie, Erica EM
A1 Shen, Junwei
A1 Gifuni, Anthony J.
A1 Ferrari, Manuela
A1 Sapra, Mamta
A1 Kloiber, Stefan
A1 Pinard, Georges-F.
A1 Dunlop, Boadie W.
A1 Looper, Karl
A1 Ranganathan, Mohini
A1 Enault, Martin
A1 Beaulieu, Serge
A1 Rej, Soham
A1 Hersson-Edery, Fanny
A1 Steiner, Warren
A1 Anacleto, Alexandra
A1 Qassim, Sabrina
A1 McGuire-Snieckus, Rebecca
A1 Margolese, Howard C.
YR 2024
UL http://medrxiv.org/content/early/2024/06/13/2024.06.13.24308884.abstract
AB Major Depressive Disorder (MDD) is a leading cause of disability and there is a paucity of tools to personalize and manage treatments. A cluster-randomized, patient-and-rater-blinded, clinician-partially-blinded study was conducted to assess the effectiveness and safety of the Aifred Clinical Decision Support System (CDSS) facilitating algorithm-guided care and predicting medication remission probabilities using clinical data. Clinicians were randomized to the Active (CDSS access) or Active-Control group (questionnaires and guidelines access). Primary outcome was remission (<11 points on the Montgomery Asberg Depression Rating Scale (MADRS) at study exit). Of 74 eligible patients, 61 (42 Active, 19 Active-Control) completed at least two MADRS (analysis set). Remission was higher in the Active group (n = 12/42 (28.6%)) compared to Active-Control (0/19 (0%)) (p = 0.01, Fisher’s exact test). No adverse events were linked to the CDSS. This is the first effective and safe longitudinal use of an artificial intelligence-powered CDSS to improve MDD outcomes.Competing Interest StatementThe authors declare the following financial interests/personal relationships which may be considered as potential competing interests: DB, KW, MR, GG, KP, JM, RF, CA, SI, CP, AA, and SQ were employees and/or shareholders of Aifred Health Inc. and supported this research in the context of their work for Aifred Health. JFK, SP are members of Aifred Health's scientific advisory board. SP has received honoraria from Aifred Health. DB, SG, EEMM, and SR receive a salary award from the Fonds de recherche du Quebec Sante (FRQS). EEMM is a Canada Research Chair (Tier 1) in Statistical Methods for Precision Medicine. BWD has received research support from Boehringer Ingelheim, Compass Pathways, Intra-Cellular Therapies, NIMH, Otsuka, Usona Institute, and has served as a consultant for Biohaven, Cerebral Therapeutics, Myriad Neuroscience, and Otsuka. SR receives grant funding from Mitacs (for a graduate student), is on a steering committee for Abbvie, and owns shares of Aifred Health. SK reports grants from the Labatt Family Innovation Fund in Brain Health (Department of Psychiatry, University of Toronto), the Max Bell Foundation, the Canadian Centre on Substance Use and Addiction, the Centre for Addiction and Mental Health Discovery Fund, the Ontario Ministry of Health and Long-Term Care (MOHLTC), the Canadian Institutes of Health Research (CIHR), and the International OCF Foundation (IOCDF). SK received honorarium for consultation from EmpowerPharm. JFK has been provided options in Aifred Health. HCM has received honoraria, sponsorship, or grants for his participation as a consultant, advisory committee member, and/or as a speaker at educational events for AbbVie, HLS Therapeutics Inc., Janssen, Lundbeck, Otsuka, Newron, Sunovion and Teva. He has received grants and/or research support from the MGH Hospital Foundation, SyneuRX and Aifred Health. SJ, TF, and YB recieved honoraria from Aifred Health for working on this paper. All other authors report no relevant conflicts.Clinical TrialNCT04655924Funding StatementFunding was provided by Aifred Health; MEDTEQ FSISSS; Bell Lets Talk and Brain Canada; Investissement Quebec; the Quebec Ministry of Economy and Innovation; the Mindstrong Foundation at the Jewish General Hospital; and the McGill Industry and Partnership grant. The study was co-designed and supervised by HM and Aifred Health. No other funder had a role in the development or reporting of this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with all relevant ethical regulations including the Declaration of Helsinki and the Tri-Council Policy Statement. The research ethics board of the Douglas Research Center gave ethical approval for this work and it was subsequently approved by central and local ethics review boards for each site. The study was conducted in accordance with Good Clinical Practice. Written informed consent was obtained from all study participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes